– USA, CA – Reviva Pharmaceuticals, Inc., (Reviva), a privately held drug discovery and development company, announced today that it has appointed life sciences industry experts, Brian G. Atwood, Sarvajna Dwivedi and Peder K. Jensen to its Board of Directors. “We are extremely pleased to welcome Mr. Atwood, Dr. Jensen and Dr. Dwivedi to the Board,” said Laxminarayan Bhat, Founder, President and Chief Executive Officer of Reviva. “With their combined extensive product development, commercialization, financial and corporate governance expertise, we are looking forward to working with them as we enter into the next stage of growth for the company.”
Mr. Atwood brings to Reviva extensive executive and financial experience. He is a co-founder and currently serves as a Managing Director for Versant Ventures, a healthcare-focused venture capital firm. Prior to launching his career in venture capital, Mr. Atwood was founder, president and CEO of Glycomed, a publicly traded biotechnology company. Mr. Atwood also serves on the boards of several pharmaceutical and biotechnology companies and holds an M.B.A. degree from Harvard University.
Dr. Dwivedi, an entrepreneur experienced in building and growing companies, brings to Reviva his extensive pharmaceutical development experience. He co-founded Pearle Therapeutics in 2006, developing inhaled medicines and their combinations for the global market in the treatment of respiratory disease. Pearle was acquired by AstraZeneca in 2013 for $1.15 billion. Prior to his industrial career, Dr. Dwivedi conducted award-winning research in pharmaceutical sciences at the University of British Columbia in Canada.
Dr. Jensen brings to Reviva over 24 years of global drug development experience in both pharmaceutical and biotechnology companies and has been responsible for more than forty new drug approvals in the U.S., Europe and Japan during his career. He most recently served as Corporate Senior Vice President and General Manager, R&D for Japan and Asia/Pacific at Schering-Plough Corporation, and earlier he held a number of global senior R&D positions at Schering-Plough, including Senior Vice President of Clinical Research. Dr. Jensen also serves on the boards of several pharmaceutical and biotechnology companies. Dr. Jensen received his M.D. from the University of Copenhagen, where he also completed his post graduate medical training in neurology and internal medicine.
About Reviva Pharmaceuticals Inc.
Reviva, located in Santa Clara, California, is a clinical stage pharmaceutical company focused on developing a portfolio of internally discovered next generation safe and effective novel therapeutic drugs by using an integrated chemical genomics approach and proprietary chemistries. Reviva is currently focused on developing ‘best in class’ new drugs for the central nervous system (CNS), metabolic, cardiovascular (CV), inflammation and pain indications. The most advanced product in the pipeline, RP5063, is an orally active new chemical entity (NCE) having effective patent life until September 2030 with possibility of patent term extension up to an additional 5 years. RP5063 is a multimodal neuromodulator in late stage clinical development for the treatment of neuropsychiatric and neurologic disorders schizophrenia, bipolar disorder, major depressive disorder (MDD), Alzheimer’s psychosis (ADP), Parkinson’s psychosis (PDP), attention deficit hyperactivity disorder (ADD/ADHD) and autism spectrum.
Reviva’s leadership team has a strong background and a track record in successful and rapid product development, regulatory approval and commercialization. Reviva was founded in 2006 and financed by high-net-worth individuals comprised of medical doctors, successful entrepreneurs, and professionals associated with the pharmaceutical and high-tech industries.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.